Clinical Trials List
2015-05-01 - 2020-04-30
Phase I/II
Terminated3
ICD-10C22.0
Liver cell carcinoma
ICD-10C22
Malignant neoplasm of liver and intrahepatic bile ducts
-
Trial Applicant
BRISTOL-MYERS SQUIBB (TAIWAN) LTD.
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/04/01
Investigators and Locations
Co-Principal Investigator
- Chih-Hung Hsu Division of Hematology & Oncology
- 廖斌志 Division of Hematology & Oncology
- Ming-Chih Ho Division of Hematology & Oncology
- YU-YUN SHAO Division of Hematology & Oncology
- Wei-Wu Chen Division of Hematology & Oncology
- 林宗哲 Division of Hematology & Oncology
- Hsiang-Fong Kao Division of Hematology & Oncology
- - - Division of Hematology & Oncology
- Ann-Lii Cheng Division of Hematology & Oncology
- 呂理駿 Division of Hematology & Oncology
- Chien-Hung Chen Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Terminated
Audit
None
Co-Principal Investigator
- Yi-Hsiang Huang Division of Hematology & Oncology
- Yee Chao Division of Hematology & Oncology
- Rheun-Chuan Lee Division of Hematology & Oncology
- Ming-Huang Chen Division of Hematology & Oncology
- Chung-Pin Li Division of Hematology & Oncology
- Yi-Ping Hung Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
9 Terminated
Audit
CRO
Co-Principal Investigator
- Wei-Chen Lee Division of Gastroenterological Surgery
- 呂嘉偉 Division of Radiology
- Shi-Ming Lin Division of Hematology & Oncology
- Tsai-Sheng Yang Division of Hematology & Oncology
- Chen-Chun Lin Division of Hematology & Oncology
- Jen-Shi Chen Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
14 Terminated
Audit
CRO
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
30 participants
-
Global
290 participants
